More Articles

Prestige and Pharmapark make deal for trastuzumab biosimilar Pharma News | Posted 09/08/2019

Singapore-based Prestige BioPharma (Prestige) and Russia-based Pharmapark announced on 8 July 2019 that they had signed an exclusive partnership and supply agreement for Prestige’s candidate trastu...

Certara technology achieves first FDA virtual bioequivalence approval for a complex generic drug Generics/News | Posted 09/08/2019

On 12 June 2019, Certara announced that its Simcyp physiologically-based pharmacokinetic (PBPK) modelling and simulation technology successfully demonstrated the bioequivalence of a complex generic...

FDA approves rituximab biosimilar Ruxience Biosimilars/News | Posted 02/08/2019

US-based pharma giant Pfizer announced on 23 July 2019 that it had received approval from the US Food and Drug Administration (FDA) for its rituximab biosimilar (PF 05280586).

Long-term safety results for adalimumab biosimilar Biosimilars/Research | Posted 02/08/2019

ABP 501 is an adalimumab biosimilar which was compared to reference adalimumab in a 24-week phase lll study demonstrating equivalent efficacy and similar safety and immunogenicity [1]. The results...

Celltrion and Nan Fung Group form joint venture for copy biologicals in China Pharma News | Posted 02/08/2019

South Korean biosimilars firm Celltrion and Hong Kong-based Nan Fung Group announced on 18 July 2019 that the two companies had formed a joint venture, Vcell Healthcare, with the aim of developing...

Positive phase III data for adalimumab copy biologicals Biosimilars/Research | Posted 02/08/2019

Positive phase III data for adalimumab copy biologicals has been presented at the European Congress of Rheumatology 2019 (EULAR 2019) [1].

Bipartisan bill aims to reduce healthcare costs in the US Policies & Legislation | Posted 02/08/2019

Senators Lamar Alexander and Patty Murray recently introduced the ‘Lower Health Care Costs Act of 2019’. The bipartisan bill includes 54 different proposals from 65 senators (36 Democrats and 29 Re...

Lannett starts phase I trial for insulin glargine biosimilar in South Africa Biosimilars/News | Posted 02/08/2019

US generics maker Lannett Company (Lannett) announced on 5 June 2019 that it had started a phase I clinical trial of its candidate insulin glargine biosimilar.